Cipla Ltd.

Financial

	Cipla	Mankind Pharma	Torrent Pharma
Operational Metrics
API Sector
US DMF Filings	2204.0 .	n/a	n/a
Pharmaceutical Sector
Number of ANDA's Filed in USA	280.0 .	60.0 .	168.0 .
Number of ANDA's Approved By USFDA	198.0 .	44.0 .	130.0 .
Domestic Sales Growth - YoY	7.1 %	n/a	13.1 %
R&D as a % of Total Sales	5.5 %	2.15 %	5.0 %
Financials
5 yr Average ROE	12.48 %	23.46 %	20.0 %
5yr average Equity Multiplier	1.31	1.37	2.34
5yr Average Asset Turnover Ratio	0.78	0.95	0.65
5yr Avg Net Profit Margin	12.29 %	17.9 %	13.21 %
Price to Book	4.2	11.37	15.34
P/E	26.64	56.77	63.88
5yr Avg Cash Conversion Cycle	-4.58 Days	-44.05 Days	-189.03 Days
Inventory Days	58.34 Days	58.78 Days	54.5 Days
Days Receivable	45.49 Days	24.18 Days	41.38 Days
Days Payable	110.05 Days	130.75 Days	318.84 Days
5yr Average Interest Coverage Ratio	33.93	56.97	5.79
5yr Avg ROCE	17.45 %	30.07 %	23.72 %
5yr Avg Operating Profit Margin	21.56 %	24.6 %	29.52 %
5 yr average Debt to Equity	0.07	0.05	0.83
5yr CAGR Net Profit	21.66 %	13.17 %	10.08 %
5yr Average Return on Assets	9.64 %	17.12 %	8.58 %
Shareholdings
Promoter Holding	30.92 %	74.87 %	71.25 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-5.2 %	-1.63 %	0.0
Change in Mutual Fund Holding (3 Yrs)	4.25 %	5.16 %	-3.02 %

Business

	Cipla	Mankind Pharma	Torrent Pharma
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 95.5 New ventures 4.5 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 US Formulations 0 Domestic formulations 0 Contract Manf. 0 Brazil/Latam 0 Germany/Europe 0	Product Wise Break-Up Neuro/CNS 5.0 Dermatology 6.0 Pharmaceutical 0 Brazil/Latam 0 New ventures 0 Germany/Europe 0 Gynaecology 6.0 Urology 3.0 Respiratory 9.0 Anti-Diabetic 7.0 Contract Manf. 0 VMN 9.0 Pain/Analgesics 5.0 Anti-infectives 16.0 Cardiovascular 14.0 US Formulations 0 Domestic formulations 0 Gastrointestinal 11.0 Others 9.0	Product Wise Break-Up Neuro/CNS 0 Dermatology 0 Pharmaceutical 0 Brazil 8.98 New ventures 0 Germany 13.15 Gynaecology 0 Urology 0 Respiratory 0 Anti-Diabetic 0 Contract Manufacturing 6.15 VMN 0 Pain/Analgesics 0 Anti-infectives 0 Cardiovascular 0 US Formulations 20.71 Domestic Formulations 42.15 Gastro - Intestinal 0 Others 8.86
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Respiratory Systems 37.5 Anti-Infective 14.0 Cardiac Science 11.4 Anti - Diabetes 5.6 Gastro Intestinal 5.4 Urology 4.7 Pain Management 3.8 Derma 3.3 Central Nervous System (CNS) 3.3 Ophthalmology 3.0 Antivirals 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Oncology 0 Others 8.0	-	-
Location Wise Break-Up	Location Wise Break-Up India 42.0 North America 28.0 SAGA 15.0 Europe 12.0 Global API 2.0 Rest of the World 0 Emerging Markets 0 Nepal 0 Sri Lanka 0 Bangladesh 0 USA 0 Germany 0 Brazil 0 Others 1.0	Location Wise Break-Up Bangladesh 0 Global API 0 Sri Lanka 0 Europe 0 USA 0 India 91.0 Rest of the World 0 Germany 0 Emerging Markets 0 Nepal 0 North America 0 Brazil 0 SAGA 0 Others 9.0	Location Wise Break-Up Bangladesh 0 Global API 0 Sri Lanka 0 Europe 0 USA 9.28 India 56.49 Rest of the World 0 Germany 9.97 Emerging Markets 0 Nepal 0 North America 0 Brazil 9.1 SAGA 0 Others 15.16
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 98.68 New Ventures 1.32	-	-
Asset Break-Up	Asset Break-Up India 46.99 USA 30.03 South Africa 18.71 Others 4.27	-	Asset Break-Up India 96.58 USA 0.32 South Africa 0 Others 3.1

Cipla Ltd.

SIGN UP FOR FREE